What is the recommended dosing regimen of enclomiphene and human chorionic gonadotropin (hCG) for a man with low testosterone who is not a candidate for testosterone replacement and wants to preserve fertility?

Enclomiphene and hCG Combination Therapy for Hypogonadism with Fertility Preservation

For men with secondary hypogonadism who desire fertility preservation, the recommended regimen is hCG 3,000 units subcutaneously every other day combined with enclomiphene citrate 12.5–25 mg daily, continued until testosterone normalizes and spermatogenesis is restored.

Why This Combination Is Recommended

Testosterone replacement therapy is absolutely contraindicated in men seeking fertility preservation because it suppresses spermatogenesis and causes prolonged, potentially irreversible azoospermia 1. The combination of hCG and enclomiphene addresses both testosterone deficiency and fertility through complementary mechanisms:

• hCG directly stimulates testicular Leydig cells to produce intratesticular testosterone at concentrations 100-fold higher than serum levels, which is essential for spermatogenesis 1, 2
• Enclomiphene blocks estrogen receptors at the hypothalamus and pituitary, reducing negative feedback and increasing endogenous LH and FSH secretion, which further supports both testosterone production and sperm development 3, 4, 5

Specific Dosing Protocol

hCG Component

• Dose: 3,000 units subcutaneously every other day (or every 3 days) 6, 7
• Route: Subcutaneous injection 7
• Duration: Continue until testosterone levels normalize (typically >300 ng/dL) and maintain until sperm appear in semen 6

Enclomiphene Component

• Dose: 12.5–25 mg orally once daily 3, 6, 5
• Timing: Take daily, preferably in the morning 6
• Duration: Continue throughout the treatment course alongside hCG 6

Expected Timeline and Outcomes

Testosterone Recovery

• Testosterone normalization typically occurs within 3–6 months, with levels reaching mid-normal range (450–600 ng/dL) 6, 5
• LH and FSH levels rise significantly with enclomiphene, confirming restoration of the hypothalamic-pituitary-gonadal axis 5

Spermatogenesis Recovery

• Return of sperm in semen occurs in approximately 47–96% of men within 4–12 months 6, 7
• Average time to first sperm appearance is 4.6 months, with mean initial sperm density of 22.6 million/mL 7
• Enclomiphene alone can achieve sperm concentrations of 75–334 million/mL in men with secondary hypogonadism 5

Clinical Pregnancy Rates

• Clinical pregnancies have been documented in men treated with this combination, though specific rates vary by baseline severity 7

Monitoring Protocol

Baseline Assessment (Before Starting Therapy)

• Confirm secondary hypogonadism: Two morning total testosterone measurements (8–10 AM) both <300 ng/dL with low or low-normal LH and FSH 1
• Baseline semen analysis to document starting sperm parameters 5, 7
• Baseline hematocrit/hemoglobin (contraindication if >54%) 1, 8
• Prolactin level if LH/FSH are low-normal to exclude hyperprolactinemia 1

Follow-Up Schedule

• Month 1–2: Check total testosterone, LH, FSH, and assess clinical response (libido, erectile function, energy) 8, 5
• Month 3: Repeat testosterone panel and first semen analysis to assess early sperm recovery 5, 7
• Month 6: Repeat testosterone, semen analysis, and hematocrit 5, 7
• Month 12: Final assessment with complete hormone panel and semen analysis 6

Target Levels During Treatment

• Total testosterone: 450–600 ng/dL (mid-normal range) 8, 5
• Sperm concentration: Goal >15 million/mL for natural conception 7
• Hematocrit: Must remain <54%; withhold therapy if exceeded 1, 8

Advantages Over Testosterone Replacement

This combination preserves fertility while treating hypogonadism, whereas testosterone therapy causes azoospermia in >90% of men within 6 months 1. Additional benefits include:

• No suppression of spermatogenesis—in fact, sperm counts increase during treatment 5, 7
• Lower risk of erythrocytosis compared to injectable testosterone (which causes hematocrit >52% in 44% of users) 8
• Maintains testicular size and function by stimulating endogenous production rather than replacing it 3, 5
• Reversible therapy—can transition to testosterone replacement after fertility goals are achieved 7

When to Add FSH

If sperm counts remain low (<5 million/mL) after 3–6 months of hCG + enclomiphene, add recombinant FSH 75–150 units subcutaneously 2–3 times weekly 1, 2, 7. This triple combination provides optimal outcomes for both testosterone normalization and spermatogenesis in men with severe secondary hypogonadism 1, 2.

Safety Profile

No significant adverse events were reported in clinical studies of this combination 6, 7. Specifically:

• No cases of treatment discontinuation due to side effects 7
• No thromboembolic events documented 8
• Gynecomastia risk is minimal because enclomiphene blocks estrogen receptors 3, 4
• Visual disturbances (rare with clomiphene) have not been reported with enclomiphene at these doses 3

Critical Pitfalls to Avoid

• Never start testosterone replacement without confirming the patient does not desire fertility—this causes prolonged azoospermia that may take 12–24 months to reverse even after stopping 1
• Do not use enclomiphene alone in men with primary hypogonadism (elevated LH/FSH), as the testes cannot respond to increased gonadotropin stimulation 2, 4
• Do not omit baseline semen analysis—you need a starting point to document improvement 5, 7
• Do not expect immediate results—counsel patients that sperm recovery takes 4–6 months on average 6, 7
• Do not continue hCG monotherapy beyond 6 months if sperm counts remain zero—add FSH at that point 1, 2, 7

When to Transition to Testosterone Replacement

Once fertility goals are achieved (documented pregnancy or completion of family planning), you can transition to standard testosterone replacement therapy for potentially greater symptomatic benefit in sexual function 1, 8. However, if sexual function improves adequately on hCG + enclomiphene, continuation is reasonable to maintain fertility potential 5.

Cost Considerations

hCG + enclomiphene is significantly more expensive than testosterone replacement (approximately $500–800/month vs. $13–180/month for testosterone), but this is the only evidence-based approach that preserves fertility while treating hypogonadism 8, 7. Insurance coverage varies, and patients should be counseled about out-of-pocket costs upfront 7.